- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07621094
Intraosseous Antibiotics for Osseointegration (IOAOI)
The purpose of this research study is to learn about the characteristics of infection in osseointegration patients. This research study will also study how safe and effective it is to use antibiotics inside the bone.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Подробное описание
The goal of this multi-center prospective trial is to assess the characteristics of infection among patients with osseointegrated prosthesis and the safety and effectiveness of intraosseous antibiotic delivery.
Participants will enroll in an observational arm. Participants who require surgery for infection may enroll in an interventional arm assessing the safety and feasibility of intraosseous antibiotic administration as a potential treatment for infection.
Тип исследования
Регистрация (Оцененный)
Фаза
- Непригодный
Контакты и местонахождение
Контакты исследования
- Имя: Christine Churchill, MA
- Номер телефона: 704-355-6947
- Электронная почта: Christine.Churchill@advocatehealth.org
Места учебы
-
-
Colorado
-
Aurora, Colorado, Соединенные Штаты, 80045
- University of Colorado Anschutz Medical Campus
-
Контакт:
- Mohamed Awad, MD
- Номер телефона: 706-832-9969
- Электронная почта: mohamed.awad@cuanschutz.edu
-
Главный следователь:
- Danielle Melton, MD
-
-
New York
-
New York, New York, Соединенные Штаты, 10021
- Hospital for Special Surgery
-
Контакт:
- Lediona Ardolli
- Номер телефона: 646-714-6362
- Электронная почта: ardollil@hss.edu
-
Главный следователь:
- S. Robert Rozbruch, MD
-
-
North Carolina
-
Charlotte, North Carolina, Соединенные Штаты, 28203
- Atrium Health Carolinas Medical Center
-
Главный следователь:
- Joseph R Hsu, MD
-
Контакт:
- Rachel B Seymour, PhD
- Номер телефона: 704-441-5365
- Электронная почта: Rachel.Seymour@advocatehealth.org
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Соединенные Штаты, 19104
- University of Pennsylvania Perelman School of Medicine
-
Главный следователь:
- Benjamin Potter, MD
-
Контакт:
- Annamarie Horan, PhD
- Номер телефона: 215-847-0132
- Электронная почта: horana@pennmedicine.upenn.edu
-
-
Texas
-
San Antonio, Texas, Соединенные Штаты, 78229
- UT Health San Antonio
-
Контакт:
- Nick Lucio, BA
- Номер телефона: 210-567-5142
- Электронная почта: luciond@uthscsa.edu
-
Главный следователь:
- Joseph Alderete, MD
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Treated with osseointegration for transfemoral, transhumeral, or transtibial amputation and presenting with concern for surgical site infection
- >18 years of age
Exclusion Criteria:
- Unable to follow up at site for 1 year
- Patients that speak neither English nor Spanish
- <18 years of age
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Нерандомизированный
- Интервенционная модель: Одногрупповое задание
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Без вмешательства: Observational
Patients that do not require surgery for infection |
|
|
Экспериментальный: Intraosseous Antibiotics for Osseointegration
Patients that require surgery for infection |
After debridement, patients will receive intraosseous (IO) vancomycin 500mg in 150ml of normal saline during surgery. The solution will be prepared by the hospital pharmacy and administered via an IO cannula. The cannula will be placed proximal to the intramedullary fixture. In cases where a tourniquet can be utilized proximal to the IO cannula, the antibiotic is delivered as a bolus. Tourniquet must be up for 1 hour after installation of the IO cases where the residual limb is too short to allow tourniquet (pneumatic or elastic) proximal to the IO cannula, the intraosseous antibiotic must be infused at a rate not to exceed 10mg/min or less. This can be accomplished by connecting intravenous tubing to the antibiotic mixture and the IO cannula. In cases without a tourniquet, IO infusion should begin during the irrigation phase and continue through the complete closure of the wound, since it requires a significant amount of time 50-60 min. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Number of Patients Who Develop Wound Dehiscence
Временное ограничение: Week 2
|
Wound Dehiscence is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart. It is Yes/No. |
Week 2
|
|
Number of Patients Who Develop Wound Dehiscence
Временное ограничение: Week 6
|
Wound Dehiscence is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart. It is Yes/No. |
Week 6
|
|
Number of Patients Who Develop Wound Dehiscence
Временное ограничение: Month 3
|
Wound Dehiscence is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart. It is Yes/No. |
Month 3
|
|
Number of Patients Who Develop Wound Dehiscence
Временное ограничение: Month 6
|
Wound Dehiscence is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart. It is Yes/No. |
Month 6
|
|
Number of Patients Who Develop Wound Dehiscence
Временное ограничение: Month 12
|
Wound Dehiscence is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart. It is Yes/No. |
Month 12
|
|
Number of Patients Who Develop Superficial Infection
Временное ограничение: Week 2
|
Superficial Infection is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart. It is yes/no. |
Week 2
|
|
Number of Patients Who Develop Superficial Infection
Временное ограничение: Week 6
|
Superficial Infection is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart. It is yes/no. |
Week 6
|
|
Number of Patients Who Develop Superficial Infection
Временное ограничение: Month 3
|
Superficial Infection is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart. It is yes/no. |
Month 3
|
|
Number of Patients Who Develop Superficial Infection
Временное ограничение: Month 6
|
Superficial Infection is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart. It is yes/no. |
Month 6
|
|
Number of Patients Who Develop Superficial Infection
Временное ограничение: Month 12
|
Superficial Infection is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart. It is yes/no. |
Month 12
|
|
Number of Patients Who Develop Deep Surgical Site Infection
Временное ограничение: Week 2
|
Number of participants in each group who develop surgical site infection as defined by the criteria establish by the Centers for Disease Control and Prevention (CDC). The CDC criteria define deep as occurring within 30 or 90 days after the procedure. However, we will continue to follow patients for 12 months and document any infections and other complications during this period. |
Week 2
|
|
Number of Patients Who Develop Deep Surgical Site Infection
Временное ограничение: Week 6
|
Number of participants in each group who develop surgical site infection as defined by the criteria establish by the Centers for Disease Control and Prevention (CDC). The CDC criteria define deep as occurring within 30 or 90 days after the procedure. However, we will continue to follow patients for 12 months and document any infections and other complications during this period. |
Week 6
|
|
Number of Patients Who Develop Deep Surgical Site Infection
Временное ограничение: Month 3
|
Number of participants in each group who develop surgical site infection as defined by the criteria establish by the Centers for Disease Control and Prevention (CDC). The CDC criteria define deep as occurring within 30 or 90 days after the procedure. However, we will continue to follow patients for 12 months and document any infections and other complications during this period. |
Month 3
|
|
Number of Patients Who Develop Deep Surgical Site Infection
Временное ограничение: Month 6
|
Number of participants in each group who develop surgical site infection as defined by the criteria establish by the Centers for Disease Control and Prevention (CDC). The CDC criteria define deep as occurring within 30 or 90 days after the procedure. However, we will continue to follow patients for 12 months and document any infections and other complications during this period. |
Month 6
|
|
Number of Patients Who Develop Deep Surgical Site Infection
Временное ограничение: Month 12
|
Number of participants in each group who develop surgical site infection as defined by the criteria establish by the Centers for Disease Control and Prevention (CDC). The CDC criteria define deep as occurring within 30 or 90 days after the procedure. However, we will continue to follow patients for 12 months and document any infections and other complications during this period. |
Month 12
|
|
Number of Patients With Treatment Failure
Временное ограничение: Week 2
|
Treatment failure is defined as explant of the OI implant for any reason. Treatment failure will also be defined as additional surgical complications, wound complications, need for chronic antibiotic suppression, readmission, and reoperation. |
Week 2
|
|
Number of Patients With Treatment Failure
Временное ограничение: Week 6
|
Treatment failure is defined as explant of the OI implant for any reason. Treatment failure will also be defined as additional surgical complications, wound complications, need for chronic antibiotic suppression, readmission, and reoperation. |
Week 6
|
|
Number of Patients With Treatment Failure
Временное ограничение: Month 3
|
Treatment failure is defined as explant of the OI implant for any reason. Treatment failure will also be defined as additional surgical complications, wound complications, need for chronic antibiotic suppression, readmission, and reoperation. |
Month 3
|
|
Number of Patients With Treatment Failure
Временное ограничение: Month 6
|
Treatment failure is defined as explant of the OI implant for any reason. Treatment failure will also be defined as additional surgical complications, wound complications, need for chronic antibiotic suppression, readmission, and reoperation. |
Month 6
|
|
Number of Patients With Treatment Failure
Временное ограничение: Month 12
|
Treatment failure is defined as explant of the OI implant for any reason. Treatment failure will also be defined as additional surgical complications, wound complications, need for chronic antibiotic suppression, readmission, and reoperation. |
Month 12
|
|
Rate of Adverse Events
Временное ограничение: Week 2
|
The proportion of participants experiencing ≥1 adverse event during the study period will be assessed to evaluate safety. Adverse events include any unfavorable or unintended medical occurrence, regardless of relatedness, including surgical, infectious, wound-related, or systemic events. Events will be collected prospectively and categorized by severity and relatedness. |
Week 2
|
|
Rate of Adverse Events
Временное ограничение: Week 6
|
The proportion of participants experiencing ≥1 adverse event during the study period will be assessed to evaluate safety. Adverse events include any unfavorable or unintended medical occurrence, regardless of relatedness, including surgical, infectious, wound-related, or systemic events. Events will be collected prospectively and categorized by severity and relatedness. |
Week 6
|
|
Rate of Adverse Events
Временное ограничение: Month 3
|
The proportion of participants experiencing ≥1 adverse event during the study period will be assessed to evaluate safety. Adverse events include any unfavorable or unintended medical occurrence, regardless of relatedness, including surgical, infectious, wound-related, or systemic events. Events will be collected prospectively and categorized by severity and relatedness. |
Month 3
|
|
Rate of Adverse Events
Временное ограничение: Month 6
|
The proportion of participants experiencing ≥1 adverse event during the study period will be assessed to evaluate safety. Adverse events include any unfavorable or unintended medical occurrence, regardless of relatedness, including surgical, infectious, wound-related, or systemic events. Events will be collected prospectively and categorized by severity and relatedness. |
Month 6
|
|
Rate of Adverse Events
Временное ограничение: Month 12
|
The proportion of participants experiencing ≥1 adverse event during the study period will be assessed to evaluate safety. Adverse events include any unfavorable or unintended medical occurrence, regardless of relatedness, including surgical, infectious, wound-related, or systemic events. Events will be collected prospectively and categorized by severity and relatedness. |
Month 12
|
|
Rate of antibiotic-complications
Временное ограничение: Week 2
|
The proportion of participants experiencing ≥1 antibiotic-related complication during treatment will be assessed. Complications include clinically significant events attributable to antibiotic exposure (e.g., allergic reactions, gastrointestinal intolerance, hepatotoxicity, nephrotoxicity, hematologic abnormalities, or local administration-related reactions). Events will be identified through clinical assessment, laboratory data, and medical record review. |
Week 2
|
|
Rate of antibiotic-complications
Временное ограничение: Week 6
|
The proportion of participants experiencing ≥1 antibiotic-related complication during treatment will be assessed. Complications include clinically significant events attributable to antibiotic exposure (e.g., allergic reactions, gastrointestinal intolerance, hepatotoxicity, nephrotoxicity, hematologic abnormalities, or local administration-related reactions). Events will be identified through clinical assessment, laboratory data, and medical record review. |
Week 6
|
|
Rate of antibiotic-complications
Временное ограничение: Month 3
|
The proportion of participants experiencing ≥1 antibiotic-related complication during treatment will be assessed. Complications include clinically significant events attributable to antibiotic exposure (e.g., allergic reactions, gastrointestinal intolerance, hepatotoxicity, nephrotoxicity, hematologic abnormalities, or local administration-related reactions). Events will be identified through clinical assessment, laboratory data, and medical record review. |
Month 3
|
|
Rate of antibiotic-complications
Временное ограничение: Month 6
|
The proportion of participants experiencing ≥1 antibiotic-related complication during treatment will be assessed. Complications include clinically significant events attributable to antibiotic exposure (e.g., allergic reactions, gastrointestinal intolerance, hepatotoxicity, nephrotoxicity, hematologic abnormalities, or local administration-related reactions). Events will be identified through clinical assessment, laboratory data, and medical record review. |
Month 6
|
|
Rate of antibiotic-complications
Временное ограничение: Month 12
|
The proportion of participants experiencing ≥1 antibiotic-related complication during treatment will be assessed. Complications include clinically significant events attributable to antibiotic exposure (e.g., allergic reactions, gastrointestinal intolerance, hepatotoxicity, nephrotoxicity, hematologic abnormalities, or local administration-related reactions). Events will be identified through clinical assessment, laboratory data, and medical record review. |
Month 12
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Patient-Reported Outcomes Measurement Information System (PROMIS -29)
Временное ограничение: 2-weeks, 6-weeks, 3-months, 6-months, 12-months
|
The PROMIS-29 is a free to use, publicly available generic health related quality of life measure that includes seven domains: depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and ability to participate in social roles and activities. A 5-point Likert scale is used for each question and norm-based total scores (range 0-100) have been calculated so that 50 represents the mean and one standard deviation is 10 points. Higher scores represent better function. |
2-weeks, 6-weeks, 3-months, 6-months, 12-months
|
|
Veterans RAND 12 (VR-12) Health Survey - Physical Component Score
Временное ограничение: 2-weeks, 6-weeks, 3-months, 6-months, 12-months
|
The VR-12 is a measure of global health that corresponds to seven domains: general health, physical functioning, role limitations, pain, fatigue, social functioning, and mental health. Together, these items are summarized into a Physical Component Score. The mean score is 50 with a standard deviation of 10. Higher scores indicate better average health (higher than 50 means better than average health, below 50 means below average health). |
2-weeks, 6-weeks, 3-months, 6-months, 12-months
|
|
Veterans Rand 12 (VR12) Health Survey - Mental Component Score
Временное ограничение: 2 weeks, 6-weeks, 3-months, 6-months, 12-months
|
The VR-12 is a measure of global health that corresponds to seven domains: general health, physical functioning, role limitations, pain, fatigue, social functioning, and mental health. Together, these items are summarized into a Mental Component Score. The mean score is 50 with a standard deviation of 10. Higher scores indicate better average health (higher than 50 means better than average health, below 50 means below average health). |
2 weeks, 6-weeks, 3-months, 6-months, 12-months
|
|
Pain - Numeric Rating Scale
Временное ограничение: 2-weeks, 6-weeks, 3-months, 6-months, 12-months
|
A scale from 0-10, where 0 is no pain and 10 is the worst pain. |
2-weeks, 6-weeks, 3-months, 6-months, 12-months
|
|
Pain - Brief Pain Inventory (BPI)
Временное ограничение: 2-weeks, 6-weeks, 3-months, 6-months, 12-months
|
The BPI is a commonly used, validated 15-item measure of pain intensity and interference with daily life. There is a pain severity score and a pain interference score. Both are 0-10, with 0 being no pain and 10 being worst pain imaginable (for pain severity) and 0 being does not interfere and 10 being completely interfered (for pain interference). Lower scores are better. |
2-weeks, 6-weeks, 3-months, 6-months, 12-months
|
Соавторы и исследователи
Соавторы
Следователи
- Главный следователь: Joseph R Hsu, MD, Wake Forest University Health Sciences
Даты записи исследования
Изучение основных дат
Начало исследования (Оцененный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- IRB00147620
- 40010222 (Другой идентификатор: Department of Defense)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .